Effect of Preoperative Chemoradiotherapy on Outcome of Patients with Locally Advanced Esophagogastric Junction Adenocarcinoma—A Pilot Study

Abstract

examination of surgical specimens demonstrated a 10% complete response rate. The median and mean survival times were 26 and 36 months respectively (95% confidence interval: 14 to 37 months and 30 to 41 months respectively). On multivariate analysis, TNM staging and clinical response were demonstrated to be the only independent variables related to long-term survival. ConclusionsIn our experience, preoperative chemoradiotherapy with folfox4 is feasible in locally advanced gej adenocarcinoma, but shows mild efficacy, as suggested by the low rate of pathologic complete response.

Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers

“…As introduced earlier, the survival rates of gastroesophageal cancers are very low. The treatment of choice remains surgical or endoscopic ablation of tumoral tissues, whereas preoperative chemotherapy and/or radiotherapy have so far shown only mild effects on response and survival, thus calling for additional therapeutic options . While there currently are no FDA‐approved EPHB4 or EFNB2‐targeting drugs, several experimental drugs have shown promise in animal models.…”

“…The treatment of choice remains surgical or endoscopic ablation of tumoral tissues, whereas preoperative chemotherapy and/or radiotherapy have so far shown only mild effects on response and survival, thus calling for additional therapeutic options. 50 While there currently are no FDA-approved EPHB4 or EFNB2-targeting drugs, several experimental drugs have shown promise in animal models. For example, studies led by the group of Krasnoperov at Only TFBS overrepresented by at least twofold over a random promoter are shown.…”

A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy

“…Chemotherapy has been shown to improve survival to >30% for those entering a curative pathway and is now an integral part of standard care either alone or in combination with radiotherapy, although the benefits of radiotherapy are greater in esophageal squamous cell carcinoma (Medical Research Council Oesophageal Cancer Working Group 2002;Cunningham et al 2006). Complete pathological response after neoadjuvant chemotherapy is rare and constitutes <15% of all cases, highlighting that residual cancer cells often remain after this treatment (Sjoquist et al 2011;Orditura et al 2014).…”

Evaluation of Tumor Resectability Rate and Pathologic Response to Preoperative Concurrent Chemoradiotherapy in Locally Advanced Proximal Gastric and Esophagogastric Junction Adenocarcinomas: A Clinical Trial

“…We found a statistically significant relation between male gender and tumor pathologic response rates to preoperative CRT as opposed to Ajani et al (7) that gender had no effect on their results. Most of our patients had ECOG PS score of 2 as opposed to some studies (13,14) that the majority of their patients had ECOG PS score of zero but like the others, this factor had no effect on treatment outcomes. In this trial, the patient BMI was a null factor on tumor resectability and pathologic response rates but high BMI was associated with increased postoperative complications.…”

“…R0 resection was observed in 77% and pCR in 26% and OS was higher in patients with CRT in comparison with others. Wydmansky et al In our study, we evaluated preoperative CRT with fluoropyrimidine based chemotherapy because these agents have approved radiosensitizing effects (13,14). We observed no significant difference in tumor pathologic response by administration of 5FU in comparison with capecitabine.…”